Merrill Ups Watson Pharmaceuticals to 'Buy'

Analyst Greg Gilbert cites the hiring of a new CFO. He says a new partnership with a generic drug maker will boost Watson's pipeline

Merrill Lynch upgraded Watson Pharmaceuticals (WPI ) to buy from neutral, and set a $40 target.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.